Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9
Abstract
:1. Introduction
2. Results
2.1. SLC26A9 and CFTR Show Distinct Expression Patterns in Control vs. CF Airway Tissues and Primary Cells
2.2. SLC26A9 Knockdown Decreases CFTR Expression and Function
2.3. SLC26A9 Overexpression Potentiates CFTR Expression and Function
2.4. Overexpression of SLC26A9 Does Not Alter the PM Expression of other CFTR Traffic Mutants
3. Discussion
4. Materials and Methods
4.1. Cell Culture
4.2. Native Human Lung Tissue
4.3. Immunofluorescence (IF) Lung Tissue Staining
4.4. Lentiviral Transduction
4.5. RT-PCR
4.6. Western Blotting
4.7. Ussing Chamber
4.8. Statistical Analyses
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
CF | Cystic Fibrosis |
CFBE | Cystic Fibrosis Bronchial Epithelial cells |
CFTR | Cystic Fibrosis Transmembrane Conductance Regulator |
ER | endoplasmic reticulum |
HEMT | highly effective modulator therapy |
PM | Plasma membrane |
SLC26A9 | Solute carrier family 26, member 9 |
References
- Amaral, M.D. Novel personalized therapies for cystic fibrosis: Treating the basic defect in all patients. J. Intern. Med. 2015, 277, 155–166. [Google Scholar] [CrossRef] [PubMed]
- Riordan, J.R.; Rommens, J.M.; Kerem, B.; Alon, N.O.A.; Rozmahel, R.; Grzelczak, Z.; Zielenski, J.; Lok, S.; Plavsic, N.; Chou, J.; et al. Identification the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989, 245, 1066–1073. [Google Scholar] [CrossRef] [PubMed]
- Hug, M.J.; Tamada, T.; Bridges, R.J. CFTR and bicarbonate secretion by epithelial cells. News Physiol. Sci. 2003, 18, 38–42. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Cutting, G.R. Cystic fibrosis genetics: From molecular understanding to clinical application. Nat. Rev. Genet. 2014, 16, 45–56. [Google Scholar] [CrossRef] [Green Version]
- Zielenski, J. Genotype and phenotype in cystic fibrosis. Respiration 2000, 67, 117–133. [Google Scholar] [CrossRef]
- Lopes-Pacheco, M. CFTR modulators: Shedding light on precision medicine for cystic fibrosis. Front. Pharmacol. 2016, 7, 1–20. [Google Scholar] [CrossRef] [Green Version]
- CFTR2 Variant List History. Available online: https://cftr2.org/mutations_history (accessed on 7 October 2021).
- Cystic Fibrosis Mutation Database. Available online: http://www.genet.sickkids.on.ca/cftr/ (accessed on 7 October 2021).
- Bell, S.C.; De Boeck, K.; Amaral, M.D. New pharmacological approaches for cystic fibrosis: Promises, progress, pitfalls. Pharmacol. Ther. 2014, 145, 19–34. [Google Scholar] [CrossRef]
- De Boeck, K.; Amaral, M.D. Progress in therapies for cystic fibrosis. Lancet Respir. Med. 2016, 4, 662–674. [Google Scholar] [CrossRef]
- Middleton, P.G.; Mall, M.A.; Dřevínek, P.; Lands, L.C.; McKone, E.F.; Polineni, D.; Ramsey, B.W.; Taylor-Cousar, J.L.; Tullis, E.; Vermeulen, F.; et al. Elexacaftor-tezacaftor-ivacaftor for cystic fibrosis with a single Phe508del allele. N. Engl. J. Med. 2019, 381, 1809–1819. [Google Scholar] [CrossRef]
- Heijerman, H.G.M.; McKone, E.F.; Downey, D.G.; Van Braeckel, E.; Rowe, S.M.; Tullis, E.; Mall, M.A.; Welter, J.J.; Ramsey, B.W.; McKee, C.M.; et al. Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: A double-blind, randomised, phase 3 trial. Lancet 2019, 394, 1940–1948. [Google Scholar] [CrossRef]
- Mount, D.B.; Romero, M.F. The SLC26 gene family of multifunctional anion exchangers. Pflug. Arch. Eur. J. Physiol. 2004, 447, 710–721. [Google Scholar] [CrossRef]
- Bertrand, C.A.; Zhang, R.; Pilewski, J.M.; Frizzell, R.A. SLC26A9 is a constitutively active, CFTR-regulated anion conductance in human bronchial epithelia. J. Gen. Physiol. 2009, 133, 421–438. [Google Scholar] [CrossRef] [Green Version]
- Dorwart, M.R.; Shcheynikov, N.; Yang, D.; Muallem, S. The solute carrier 26 family of proteins in epithelial ion transport. Physiology 2008, 23, 104–114. [Google Scholar] [CrossRef] [Green Version]
- Balázs, A.; Mall, M.A. Role of the SLC26A9 chloride channel as disease modifier and potential therapeutic target in cystic fibrosis. Front. Pharmacol. 2018, 9, 1112. [Google Scholar] [CrossRef]
- Strug, L.J.; Gonska, T.; He, G.; Keenan, K.; Ip, W.; Böelle, P.Y.; Lin, F.; Panjwani, N.; Gong, J.; Li, W.; et al. Cystic fibrosis gene modifier SLC26A9 modulates airway response to CFTR-directed therapeutics. Hum. Mol. Genet. 2016, 25, 4590–4600. [Google Scholar]
- Corvol, H.; Mésinèle, J.; Douksieh, I.H.; Strug, L.J.; Boëlle, P.Y.; Guillot, L. SLC26A9 gene is associated with lung function response to ivacaftor in patients with cystic fibrosis. Front. Pharmacol. 2018, 9, 828. [Google Scholar] [CrossRef]
- Kmit, A.; Marson, F.A.L.; Pereira, S.V.N.; Vinagre, A.M.; Leite, G.S.; Servidoni, M.F.; Ribeiro, J.D.; Ribeiro, A.F.; Bertuzzo, C.S.; Amaral, M.D. Extent of rescue of F508del-CFTR function by VX-809 and VX-770 in human nasal epithelial cells correlates with SNP rs7512462 in SLC26A9 gene in F508del/F508del Cystic Fibrosis patients. Biochim. Biophys. Acta—Mol. Basis. Dis. 2019, 1865, 1323–1331. [Google Scholar] [CrossRef]
- Sun, L.; Rommens, J.M.; Corvol, H.; Li, W.; Li, X.; Chiang, T.A.; Lin, F.; Dorfman, R.; Busson, P.F.; Parekh, R.V.; et al. Multiple apical plasma membrane constituents are associated with susceptibility to meconium ileus in individuals with cystic fibrosis. Nat. Genet. 2012, 44, 562–569. [Google Scholar] [CrossRef]
- Li, W.; Soave, D.; Miller, M.R.; Keenan, K.; Lin, F.; Gong, J.; Chiang, T.; Stephenson, A.L.; Durie, P.; Rommens, J.; et al. Unraveling the complex genetic model for cystic fibrosis: Pleiotropic effects of modifier genes on early cystic fibrosis-related morbidities. Hum. Genet. 2014, 133, 151–161. [Google Scholar] [CrossRef]
- Miller, M.R.; Soave, D.; Li, W.; Gong, J.; Pace, R.G.; Boëlle, P.Y.; Cutting, G.R.; Drumm, M.L.; Knowles, M.R.; Sun, L.; et al. Variants in solute carrier SLC26A9 modify prenatal exocrine pancreatic damage in cystic fibrosis. J. Pediatr. 2015, 166, 1152–1157.e6. [Google Scholar] [CrossRef] [Green Version]
- Lam, A.T.N.; Aksit, M.A.; Vecchio-Pagan, B.; Shelton, C.A.; Osorio, D.L.; Anzmann, A.F.; Goff, L.A.; Whitcomb, D.C.; Blackman, S.M.; Cutting, G.R. Increased expression of anion transporter SLC26A9 delays diabetes onset in cystic fibrosis. J. Clin. Investig. 2020, 130, 272–286. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Anagnostopoulou, P.; Riederer, B.; Duerr, J.; Michel, S.; Binia, A.; Agrawal, R.; Liu, X.; Kalitzki, K.; Xiao, F.; Chen, M.; et al. SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. J. Clin. Investig. 2012, 122, 3629–3634. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ousingsawat, J.; Schreiber, R.; Kunzelmann, K. Differential contribution of SLC26A9 to Cl− conductance in polarized and non-polarized epithelial cells. J. Cell. Physiol. 2012, 227, 2323–2329. [Google Scholar] [CrossRef] [PubMed]
- Avella, M.; Loriol, C.; Boulukos, K.; Borgese, F.; Ehrenfeld, J. SLC26A9 stimulates CFTR expression and function in human bronchial cell lines. J. Cell. Physiol. 2011, 226, 212–223. [Google Scholar] [CrossRef]
- Sato, Y.; Thomas, D.Y.; Hanrahan, J.W. The anion transporter SLC26A9 localizes to tight junctions and is degraded by the proteasome when co-expressed with F508del-CFTR. J. Biol. Chem. 2019, 294, 18269–18284. [Google Scholar] [CrossRef]
- Bertrand, C.A.; Mitra, S.; Mishra, S.K.; Wang, X.; Zhao, Y.; Pilewski, J.M.; Madden, D.R.; Frizzell, R.A. The CFTR trafficking mutation F508del inhibits the constitutive activity of SLC26A9. Am. J. Physiol.—Lung. Cell. Mol. Physiol. 2017, 312, L12–L925. [Google Scholar] [CrossRef]
- Ruan, Y.C.; Wang, Y.; da Silva, N.; Kim, B.; Diao, R.Y.; Hill, E.; Brown, D.; Chan, H.C.; Breton, S. CFTR interacts with ZO-1 to regulate tight junction assembly and epithelial differentiation through the ZONAB pathway. J. Cell Sci. 2014, 127, 4396–4408. [Google Scholar]
- De Lisle, R.C. Disrupted tight junctions in the small intestine of cystic fibrosis mice. Cell Tissue Res. 2014, 355, 131–142. [Google Scholar] [CrossRef] [Green Version]
- Laselva, O.; Bartlett, C.; Popa, A.; Ouyang, H.; Gunawardena, T.N.A.; Gonska, T.; Moraes, T.J.; Bear, C.E. Emerging preclinical modulators developed for F508del-CFTR have the potential to be effective for ORKAMBI resistant processing mutants. J. Cyst. Fibros. 2021, 20, 106–119. [Google Scholar] [CrossRef]
- Quaresma, M.C.; Pankonien, I.; Clarke, L.A.; Sousa, L.S.; Silva, I.A.L.; Railean, V.; Doušová, T.; Fuxe, J.; Amaral, M.D. Mutant CFTR Drives TWIST1 mediated epithelial–mesenchymal transition. Cell Death Dis. 2020, 11, 920. [Google Scholar] [CrossRef]
- LeSimple, P.; Liao, J.; Robert, R.; Gruenert, D.C.; Hanrahan, J.W. Cystic fibrosis transmembrane conductance regulator trafficking modulates the barrier function of airway epithelial cell monolayers. J. Physiol. 2010, 588, 1195–1209. [Google Scholar] [CrossRef]
- Laselva, O.; Bartlett, C.; Gunawardena, T.N.A.; Ouyang, H.; Eckford, P.D.W.; Moraes, T.J.; Bear, C.E.; Gonska, T. Rescue of multiple class II CFTR mutations by elexacaftor+tezacaftor+ ivacaftor mediated in part by the dual activities of elexacaftor as both corrector and potentiator. Eur. Respir. J. 2021, 57, 2002774. [Google Scholar] [CrossRef]
- Amatngalim, G.D.; Rodenburg, L.W.; Aalbers, B.L.; Raeven, H.H.M.; Aarts, E.M.; Silva, I.A.L.; Nijenhuis, W.; Vrendenbarg, S.; Kruisselbrink, E.; Brunsveld, J.E.; et al. CFTR modulator response measurements in subjects with cystic fibrosis using 2D differentiated nasal epithelia converted into spheroids. bioRxiv 2021. [Google Scholar] [CrossRef]
- Schindelin, J.; Arganda-Carreras, I.; Frise, E.; Kaynig, V.; Longair, M.; Pietzsch, T.; Preibisch, S.; Rueden, C.; Saalfeld, S.; Schmid, B.; et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods 2012, 9, 676–682. [Google Scholar] [CrossRef] [Green Version]
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Pinto, M.C.; Quaresma, M.C.; Silva, I.A.L.; Railean, V.; Ramalho, S.S.; Amaral, M.D. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9. Int. J. Mol. Sci. 2021, 22, 13064. https://doi.org/10.3390/ijms222313064
Pinto MC, Quaresma MC, Silva IAL, Railean V, Ramalho SS, Amaral MD. Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9. International Journal of Molecular Sciences. 2021; 22(23):13064. https://doi.org/10.3390/ijms222313064
Chicago/Turabian StylePinto, Madalena C., Margarida C. Quaresma, Iris A. L. Silva, Violeta Railean, Sofia S. Ramalho, and Margarida D. Amaral. 2021. "Synergy in Cystic Fibrosis Therapies: Targeting SLC26A9" International Journal of Molecular Sciences 22, no. 23: 13064. https://doi.org/10.3390/ijms222313064